EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical.

Slides:



Advertisements
Similar presentations
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Advertisements

Ali Alsayegh, MD, FRCPC,FACC Consultant Cardiologist, Consultant Cardiac Electrophysiologist.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.
IMPANTABLE CARDIOVERTER DEFIBRILLATORS (ICDs) Janet McComb Freeman Hospital Newcastle upon Tyne.
PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Implantable Cardioverter Defibrillator Rebecca Boduch Biomedical Engineering University of Rhode Island.
Arrhythmias: The Good, the Bad and the Ugly
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Juan Camilo Diaz Cardiac Pacemakers.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Arrhytmia In Heart Failure
Pacemakers and Implanted Defibrillators Mike Harlan.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
The EP show: Brugada Syndrome Eric Prystowsky, MD Director
Heart Failure Ben Starnes MD FACC Interventional Cardiology
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Amiodarone Use in Cardiac Surgical Resuscitation
EP Show – Aug 2003 ICDs – Primary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical.
Pacemakers and Implantable Cardioverter Defibrillators Chapter 10
Device-Based Therapy of Cardiac Rhythm Abnormalities
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
New guidelines for CABG
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Eric Prystowsky, MD Director Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, IN Dan Roden, MD Director Division of Clinical Pharmacology,
Sudden Cardiac Death; Invasive Evaluation Alpay Çeliker MD Hacettepe University Department of Pediatric Cardiology Ankara, Türkiye.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
First author: Sendrea Octavian-Laurentiu Coordinator: Senior Lecturer Gozar Liliana, MD, PhD.
EP Show – April 2002 MADIT II The EP Show: MADIT II Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.
Ablation: past, present, and future Dr Eric Prystowsky Director Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis Dr Mel Scheinman.
EP Show – December 2002 AFFIRM The EP Show: AFFIRM Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.
Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.
New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology
BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Pacemakers.
Device and Antiarrhythmic Drugs: Advantages and Pitfalls Teresa Menendez Hood, M.D.
William M. Miles, MD, FHRS University of Florida College of Medicine Gainesville, FL ICD Implantation: Genetic Arrhythmia Syndromes.
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
Dr Eric Prystowsky Director Clinical Electrophysiology Laboratory St Vincent Hospital, Indianapolis Dr Leslie Saxon Chief, Electrophysiology Laboratory.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.
© 2008, American Heart Association. All rights reserved. AHA/ACC/HRS Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
Ethical Scenario: Cardiovascular System
Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.
Implantable Defibrillator Therapy Post Cardiac Arrest
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
American College of Cardiology Presented by Dr. Stuart J. Connolly
Pacemakers and Implantable Cardioverter-Defibrillators
Arrhythmia Arrhythmia.
Preventing SCD With a WCD: Reviewing the Results of the VEST Trial
Dirty Laundry.
The most common cause of death in North America is cardiac death and the most common cause of cardiac death is sudden death from ventricular arrhythmias.
The EP show: sudden death, part 1 Director
European Heart Association Journal 2007 April
David D. Berg et al. JACC 2018;71:
Belinda Gray et al. JCHF 2013;1:
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
The EP Show: CMS reimbursement decision for ICDs
Mahesh Anantha Narayanan et al. JACEP 2017;3:
Volume 12, Issue 10, Pages (October 2015)
Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep
Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, IN Helmut Klein MD Head of Division of Cardiology Otto-von-Guericke Universität Magdeburg Magdeburg, Germany Paul Dorian MD Professor of Medicine Division of cardiology St. Michael's Hospital Toronto, ON

EP Show – Aug 2003 ICDs – Secondary prevention Secondary prevention Secondary prevention patients Documented history of cardiac arrest due to ventricular abnormality Documented sustained ventricular tachycardia with symptoms requiring intervention Syncope due to a ventricular arrhythmia Dorian

EP Show – Aug 2003 ICDs – Secondary prevention Patients at risk Any patient with a sustained life-threatening arrhythmia without reversible cause is at very high risk without treatment Prognosis of patients with sustained ventricular tachycardia in the presence of heart disease is as bad as for those with a history of cardiac arrest Dorian

EP Show – Aug 2003 ICDs – Secondary prevention Clinical trials

EP Show – Aug 2003 ICDs – Secondary prevention Consensus Consensus has been reached that someone who is at high risk of sudden cardiac death is best treated by an ICD Questions remain about how to treat a patient suffering cardiac arrest in the context of another severe illness Dorian

EP Show – Aug 2003 ICDs – Secondary prevention Amiodarone? In a debate Stuart Connelly suggested amiodarone is a reasonable alternative for patients with EF >35% 11-year mortality follow-up of CIDS ICD (%) (n=60) Amiodarone (%) (n=60) HR Annual mortality rate (p=0.0231) Dorian P et al. AHA 2002

EP Show – Aug 2003 ICDs – Secondary prevention Two questions What is the role of amiodarone in Europe? Are we really able to determine what is and isn't reversible cause? "Maybe we're not so smart in picking up reversible causes." Prystowsky

EP Show – Aug 2003 ICDs – Secondary prevention Amiodarone in Europe Amiodarone in patients with better EF: Was originally thought the ideal ICD candidate would have better EF Reality is that incidence of sudden death is much higher in patients with low EF, and ICDs are much more effective there Europe is coming over to the idea of ICDs as the main approach Klein

EP Show – Aug 2003 ICDs – Secondary prevention Ventricular function changes "You never know when the ventricular performance changes and gets worse. Impaired ventricular function is not a sign that starts with one symptom and then you know." A patient can have a small ischemic event without noticing and suddenly drop in ejection fraction Klein

EP Show – Aug 2003 ICDs – Secondary prevention ICDs first Patients who have had a cardiac arrest, regardless of reason, need an ICD Amiodarone can be used as additional therapy or for those who may have recurring sustained ventricular tachycardia to limit ventricular intervention Klein

EP Show – Aug 2003 ICDs – Secondary prevention Follow-up A major limitation of the the major ICD trials is that follow-up was only two to three years but the disease is a chronic one "The severity of the underlying heart disease is a moving target, and the sad reality is that the trajectory of the severity of heart disease is such that most patients over the long term will get worse." Dorian

EP Show – Aug 2003 ICDs – Secondary prevention ICDs over time The trials don't tell us, but the probability of benefiting from an ICD will increase over time Improvements in heart-failure therapy mean most patients receiving ICDs for secondary prevention do live five years or more Dorian

EP Show – Aug 2003 ICDs – Secondary prevention Long-term mortality Measure ICD (n=60) Amiodarone (n=60) HR Annual mortality rate 4.8%8.4%2.01 (p=0.0231) Total number of deaths 1628NA 11-year mortality follow-up of CIDS Dorian P, et al. AHA 2002

EP Show – Aug 2003 ICDs – Secondary prevention Reversible cause There are still some reversible causes that are undisputed and are acceptably called "reversible cause": A patient comes in with clearly identifiable AMI and has VF in the first 6 to 24 hours is a true reversible cause For a hyperkalemia patient, is a K of 2.9 reversible? Prystowsky

EP Show – Aug 2003 ICDs – Secondary prevention Hypokalemia During cardiac arrest potassium is taken up inside cells, and so the initial potassium measurement in most patients will be low "It's probably better to think of hypokalemia as a trigger, rather than as a cause, of the cardiac arrest." Dorian

EP Show – Aug 2003 ICDs – Secondary prevention Potassium If it is truly hypokalemia you ought to repeat the measurement six to eight hours later If K is now 4.0 with minimal repletion of potassium then patient needs an ICD If K is still in the mid- to high-2 range six to eight hours later then they probably really do have hypokalemia Prystowsky

EP Show – Aug 2003 ICDs – Secondary prevention Single or dual chamber? We accept you must be careful what you call reversible, and ICDs are the treatment of choice Do we use single or dual chambers, and have the data from DAVID changed your approach? Prystowsky

EP Show – Aug 2003 ICDs – Secondary prevention Unnecessary pacing "Continuously pacing means that you create an asynchronous ventricular contraction." Avoiding pacing when possible is better than just sensing the atrium and pacing the right ventricle continuously If there is compelling reason such as sinus- node dysfunction then dual-chamber pacing could be used Klein

EP Show – Aug 2003 ICDs – Secondary prevention Single- or dual-chamber ICD? "We changed our mind just recently because of the DAVID trial." Klein Proportion of single- and dual-chamber pacing? Klein: 80% single/20% dual Dorian: 30% to 40% single/60% to 70% dual

EP Show – Aug 2003 ICDs – Secondary prevention Dual-chamber ICDs Dual-chamber ICDs offer the ability to discriminate between supraventricular tachycardia and tachycardia Programmed for minimum pacing: backup rate <50 beats/minute and longest AV delay possible "That allows us to then derive the benefit for the atrial signal for discrimination without the cost of the unwanted ventricular pacing." Dorian

EP Show – Aug 2003 ICDs – Secondary prevention Minimize pacing Must minimize the amount of time pacing the ventricle, don't pace unless you have to Decision on single vs dual chamber will depend on the individual implanter and the particular patient "How you actually select who gets the atrial lead will depend on your own philosophy." Prystowsky

EP Show – Aug 2003 ICDs – Secondary prevention Economics With less economic pressure, I lean toward using a dual-chamber ICD with minimal programming "I would be the first to admit to you that if someone shut me down economically for any reason, that I could either get two defibrillators or one with dual-chamber capability, I'd take two defibrillators." Prystowsky

EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, IN Helmut Klein MD Head of Division of Cardiology Otto-von-Guericke Universität Magdeburg Magdeburg, Germany Paul Dorian MD Professor of Medicine Division of cardiology St. Michael's Hospital Toronto, ON